Unscripted.
Patel
Preethi
P
Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. patelp3@ccf.org
Dhaliwal
Gurpreet
G
Rajamanickam
Anitha
A
Gebresalassie
Surafel
S
Harte
Brian
B
D051722:ADAM Proteins / Q000032:analysis; D000071120:ADAMTS13 Protein; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D015897:Comorbidity; D003937:Diagnosis, Differential; D006461:Hemolysis; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000209:etiology; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy*; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D000925:Anticoagulants; D007166:Immunosuppressive Agents; D014859:Warfarin; D006493:Heparin; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human